Septerna (NASDAQ:SEPN) Stock Price Up 7.5% – What’s Next?

Septerna, Inc. (NASDAQ:SEPN) shot up 7.5% during trading on Tuesday . The stock traded as high as $26.70 and last traded at $26.7470. 121,116 shares were traded during mid-day trading, a decline of 64% from the average session volume of 337,907 shares. The stock had previously closed at $24.88.

Wall Street Analyst Weigh In

SEPN has been the topic of a number of recent research reports. Wall Street Zen cut shares of Septerna from a “strong-buy” rating to a “buy” rating in a report on Saturday. Truist Financial initiated coverage on Septerna in a research report on Monday, December 15th. They set a “buy” rating and a $34.00 price target on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Septerna in a report on Wednesday, October 8th. Wells Fargo & Company upgraded Septerna from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $18.00 to $28.00 in a research note on Friday, November 14th. Finally, Raymond James Financial initiated coverage on Septerna in a research note on Friday, December 19th. They issued a “strong-buy” rating and a $38.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $33.00.

Septerna Trading Up 6.0%

The company has a market cap of $1.18 billion, a price-to-earnings ratio of -17.47 and a beta of 3.85. The stock has a 50-day simple moving average of $25.49 and a 200-day simple moving average of $18.89.

Septerna (NASDAQ:SEPN) last released its earnings results on Monday, November 10th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of $0.19 by ($0.28). The company had revenue of $21.50 million for the quarter, compared to analyst estimates of $24.50 million. Septerna had a negative net margin of 266.77% and a negative return on equity of 17.98%. As a group, research analysts expect that Septerna, Inc. will post -7.11 EPS for the current fiscal year.

Insiders Place Their Bets

In other Septerna news, SVP Daniel D. Long sold 3,501 shares of the company’s stock in a transaction that occurred on Monday, November 10th. The stock was sold at an average price of $18.06, for a total value of $63,228.06. Following the completion of the sale, the senior vice president directly owned 92,911 shares in the company, valued at $1,677,972.66. This represents a 3.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 4.30% of the stock is owned by company insiders.

Institutional Trading of Septerna

Several institutional investors have recently modified their holdings of SEPN. Perceptive Advisors LLC acquired a new position in Septerna during the second quarter worth about $5,723,000. VR Adviser LLC acquired a new position in shares of Septerna in the 2nd quarter worth approximately $5,713,000. Millennium Management LLC raised its holdings in shares of Septerna by 639.6% in the 3rd quarter. Millennium Management LLC now owns 384,200 shares of the company’s stock worth $7,227,000 after purchasing an additional 332,256 shares in the last quarter. ADAR1 Capital Management LLC lifted its stake in Septerna by 38.9% during the third quarter. ADAR1 Capital Management LLC now owns 1,176,491 shares of the company’s stock valued at $22,130,000 after purchasing an additional 329,264 shares during the last quarter. Finally, Woodline Partners LP boosted its holdings in Septerna by 94.2% during the first quarter. Woodline Partners LP now owns 582,585 shares of the company’s stock worth $3,373,000 after buying an additional 282,585 shares in the last quarter.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.